Elixinol Wellness Limited (ASX: EXL / OTC: ELLXF) – Ramping Up Revenue While Slashing Costs
Highlights In 2022, revenue fell 24% YoY to $7.1M, but beat our estimate by 8%. Revenue declined...
Read MoreHighlights In 2022, revenue fell 24% YoY to $7.1M, but beat our estimate by 8%. Revenue declined...
Read MoreHighlights This company develops and sells hemp-derived CBD nutraceutical, cosmetic, and food...
Read More